Cholesterol · LIPID · Homo sapiens
This target will appear in recent viewed items on this browser. Use the demo workspace to preview watch rules and decision queues.
Move to another high-traffic target or paste a specific ChEMBL target ID.
Structured disease, protein, and project context should read before the lower-level identity rail.
As of 2026-09-14Cholesterol shows late clinical disease relevance led by Niemann-Pick disease type C. 2 more disease programs remain visible in the same review block. 1 linked drug keeps the current disease frame grounded. Use Niemann-Pick disease type C as the disease frame, then confirm a stable protein accession before cross-source reuse.
Use Niemann-Pick disease type C as the disease frame, then confirm a stable protein accession before cross-source reuse.
Cholesterol shows late clinical disease relevance led by Niemann-Pick disease type C. 2 more disease programs remain visible in the same review block. 1 linked drug remains visible in the same block.
Start review with Niemann-Pick disease type C because it currently carries late clinical support. Linked drugs include 2-HYDROXYPROPYL-BETA-CYCLODEXTRIN. This disease block keeps the Open Targets-ready contract explicit while current evidence comes from ChEMBL mechanism and indication mappings.
Disease source · ChEMBL drug mechanism + indication proxyCholesterol
Review this target as Cholesterol.
Protein source · UniProt accession via ChEMBL component mappingKeep the review anchor, source IDs, and context contract aligned before reusing this target elsewhere.
This review treats Cholesterol as ChEMBL target CHEMBL4651303. Disease framing currently uses the Open Targets-ready proxy contract.
Reuse the same identifiers in notes, watch rules, exports, and review packs so provenance stays stable across surfaces.
Choose the first block or source based on the question you are trying to answer.
Start here when your first question is whether Cholesterol still has a stable protein naming contract across sources.
Jump to Protein ContextUse this block first when you need to confirm why Niemann-Pick disease type C is currently framed as late clinical support. It currently carries 1 linked drug in the same disease frame.
Jump to Disease ContextOpen the one-page evidence card when you want the rationale, activity base, and attribution together.
Open Review-ready CardVerify identity, organism, and the fastest next research jumps from the same page.
| Preferred Name | Cholesterol |
| Target Type | LIPID |
| Organism | Homo sapiens |
Reviewable protein naming and mapping context for this target snapshot.
Review this target as Cholesterol.
Open Targets-ready disease context using the current target-indication evidence contract.
Cholesterol shows late clinical disease relevance led by Niemann-Pick disease type C. 2 more disease programs remain visible in the same review block.
Start review with Niemann-Pick disease type C because it currently carries late clinical support. Linked drugs include 2-HYDROXYPROPYL-BETA-CYCLODEXTRIN. This disease block keeps the Open Targets-ready contract explicit while current evidence comes from ChEMBL mechanism and indication mappings.